Case studies

ICON provided a tailored quantitative risk assessment solution to help a sponsor anonymize clinical study data and documents for regulatory submission and private data-sharing.

A small US based biotechnology company sought ICON’s assistance for a high-risk immunology study with heavy investment and limited resources. The study was a phase 3 Lupus SLE study with a complex protocol governing 90 sites.

For this client, ICON has performed technical evaluations of more than sixty assets across a range of therapeutic areas and modalities, including assessing the development risks and probability of achieving registration and commercial success.

Small biotech companies were key to pushing forward their research on mRNA and associated technologies and adapting candidate vaccines to combat COVID-19. ICON was ideally placed to partner with these sponsors during the COVID-19 global pandemic.

ICON was approached by a customer seeking our expertise in conducting drug asset evaluation consulting services. The client looked to evaluate pharmaceuticals suitable for in-licensing or co-development, placing particular emphasis on autoimmune diseases.

ICON collaborated with the trial sponsor to identify opportunities for improving specific processes related to electronic data capture (EDC) build for select studies.
Through a comprehensive SWOT analysis of a suite of studies, ICON identified areas for study build process improvements across the entire portfolio.

We created a more sustainable organisational design for our partner, within their Data Management and Biostatistics functions, resulting in a 56% cost saving.

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

Read more about how we consolidated over 340 site management resources, from 70 vendors, across 30 countries resulting in a 91% reduction in client burden.

In a multi-vendor FSP model for clinical monitoring, the client required the capability to aggregate and analyse data internally across all FSP providers.

Due to unprecedented resourcing needs prompted by the COVID-19 pandemic, our large pharma partner required rapid and efficient resource allocation in an FSP model to reduce turnover and promote growth.

A venture-backed biopharmaceutical company focused on therapies for rare diseases needed to accelerate late-stage development and commercialization. ICON provided technical and commercial assessments, collaborating closely to simplify the development program and develop ePROs and a novel biomarker approach for the rare disease asset.